Literature DB >> 8930157

Molecular basis and species specificity of high affinity binding of vasoactive intestinal polypeptide by the rat secretin receptor.

M H Holtmann1, E M Hadac, C D Ulrich, L J Miller.   

Abstract

The affinity and specificity of the binding interaction between ligands and their receptors are key for appropriate hormonal regulation of target tissues. However, it is now apparent that vasoactive intestinal polypeptide (VIP) binds to the rat secretin receptor with similar affinity to that for its natural ligand, secretin (Holtmann et al., 1995). In this report, we establish that this is not a characteristic of the human secretin receptor, and use rat-human secretin receptor chimeras, site mutants and truncated receptor constructs to establish the molecular basis for this unusual binding interaction. Of note, isolated N-terminal domains of the rat secretin and the VIP receptors are capable of high affinity binding of VIP. In the recently recognized secretin family of receptors, this domain has six conserved cysteine residues and disulfide bonds that are likely important to achieve the complex conformation critical for this binding. A single acidic residue (Asp98) present in the rat secretin receptor appears to be critical, because a site-mutant changing this to the polar, but uncharged residue present in that position in the human receptor (Asn) eliminates the high affinity binding of VIP. Of interest, a previously identified critical basic residue in VIP (Lys15) provides a candidate for charge-pairing with this residue, potentially aligning the peptide ligand in a nonproductive orientation within this receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930157

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Juxtamembranous region of the amino terminus of the family B G protein-coupled calcitonin receptor plays a critical role in small-molecule agonist action.

Authors:  Maoqing Dong; Richard F Cox; Laurence J Miller
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

2.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

3.  Combined administration of secretin and oxytocin inhibits chronic colitis and associated activation of forebrain neurons.

Authors:  Martha G Welch; Muhammad Anwar; Christine Y Chang; Kara J Gross; David A Ruggiero; Hadassah Tamir; Michael D Gershon
Journal:  Neurogastroenterol Motil       Date:  2010-03-04       Impact factor: 3.598

4.  Secretin receptor-deficient mice exhibit impaired synaptic plasticity and social behavior.

Authors:  Ichiko Nishijima; Takanori Yamagata; Corinne M Spencer; Edwin J Weeber; Olga Alekseyenko; J David Sweatt; Mariko Y Momoi; Masayuki Ito; Dawna L Armstrong; David L Nelson; Richard Paylor; Allan Bradley
Journal:  Hum Mol Genet       Date:  2006-09-28       Impact factor: 6.150

5.  Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.

Authors:  J Van Rampelbergh; M G Juarranz; J Perret; A Bondue; R M Solano; C Delporte; P De Neef; P Robberecht; M Waelbroeck
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

6.  Secretin stimulates biliary cell proliferation by regulating expression of microRNA 125b and microRNA let7a in mice.

Authors:  Shannon Glaser; Fanyin Meng; Yuyan Han; Paolo Onori; Billy K Chow; Heather Francis; Julie Venter; Kelly McDaniel; Marco Marzioni; Pietro Invernizzi; Yoshiyuki Ueno; Jia-ming Lai; Li Huang; Holly Standeford; Domenico Alvaro; Eugenio Gaudio; Antonio Franchitto; Gianfranco Alpini
Journal:  Gastroenterology       Date:  2014-02-25       Impact factor: 22.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.